Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 6
Submit an article Journal homepage
1,701
Views
1
CrossRef citations to date
0
Altmetric
Influenza – Research Article

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Xiaoqiang Liua Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan, ChinaView further author information
,
Juliana Parkb Global Clinical Development, Sanofi, Sydney, AustraliaCorrespondence[email protected]
View further author information
,
Shengli Xiac Institute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan, ChinaView further author information
,
Bin Liangd China Medical, Sanofi, Beijing, ChinaView further author information
,
Shuangmin Yanga Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan, ChinaView further author information
,
Yanxia Wangc Institute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan, ChinaView further author information
,
Olga Syrkinae Global Pharmacovigilance, Sanofi, Swiftwater, Pennsylvania, USAView further author information
,
Nathalie Lavisf Global Medical, Sanofi, Lyon, FranceView further author information
,
Shuzhen Liug Department of Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Chenyan Zhaog Department of Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Jian Dingd China Medical, Sanofi, Beijing, ChinaView further author information
,
Jieqiong Hub Global Clinical Development, Sanofi, Sydney, AustraliaView further author information
,
Sandrine I. Samsonf Global Medical, Sanofi, Lyon, FranceView further author information
,
Iris A. de Bruijnh Global Clinical Development, Sanofi, Marcy l’Etoile, FranceView further author information
& for the FSQ01 and FSQ02 Study Groups show all
Article: 2132798 | Received 01 Jun 2022, Accepted 01 Oct 2022, Published online: 03 Nov 2022

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.